WO2005012268A1 - イソオキサゾール環を有するスルホンアミド誘導体 - Google Patents
イソオキサゾール環を有するスルホンアミド誘導体 Download PDFInfo
- Publication number
- WO2005012268A1 WO2005012268A1 PCT/JP2004/010697 JP2004010697W WO2005012268A1 WO 2005012268 A1 WO2005012268 A1 WO 2005012268A1 JP 2004010697 W JP2004010697 W JP 2004010697W WO 2005012268 A1 WO2005012268 A1 WO 2005012268A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- formula
- optionally substituted
- hydroxy
- substituted
- lower alkyl
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/08—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
- A61P33/06—Antimalarials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Definitions
- Patent Document 6 International Publication No. (
- R 2 and R 2 ′ are each independently a hydrogen atom, an optionally substituted lower alkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted aryl, a heteroaryl, Substituted or substituted, heteroarylalkyl;
- R 3 may be a hydrogen atom, an optionally substituted lower alkyl, an optionally substituted aryl, an optionally substituted aralkyl, an optionally substituted heteroaryl, or a substituted Les, heteroarylalkyl;
- T is a group represented by
- 13 ⁇ 4 4 is 1, 4-phenylene or 2
- 5-Chiofenjiiru a is 1) compounds described according to any one 7), its optically active substance, or pharmaceutically acceptable salts thereof, Or their solvates.
- a pharmaceutical composition comprising the compound according to any one of 1) to 15) as an active ingredient.
- non-aromatic heterocyclic ring used alone or in combination with other terms includes one or more arbitrarily selected oxygen, sulfur or nitrogen atoms in the ring. Includes non-aromatic 5- to 7-membered rings, including the above, or rings obtained by condensing two or more of them.
- examples of "asyloxy” include acetyloxy, propionyloxy, benzoyloxy and the like.
- examples of the substituent in the "optionally substituted lower alkyl” include cycloalkyl, hydroxy, lower alkyloxy, menolecapto, lower alkylthio, halogen, nitro, carboxy, and lower alkylo.
- Halogen, lower alkyl, lower alkyloxy, lower alkylthio, halo-lower alkyl, halo-lower alkyloxy, halo-lower alkylthio, hydroxy, hydroxy-lower alkyl, acyl, nitro, samino or optionally substituted amino are preferred.
- the distal part of the right femur and the proximal part of the tibia are collected.
- the cartilage surface is photographed with a digital camera (Nikon).
- the total area of the medial tibia and the staining area are measured using image analysis software (Win Roof, manufactured by MITANI CORPORATION).
- N-chlorosuccinimide (450 mg, 3.33 mmol) was added to a solution of 4_methylbenzaldoxime (6) (452 mg, 3.33 mmol) in dimethylformamide (4 mL) under an argon atmosphere. The mixture was stirred at C for 1 hour. After cooling on ice, a solution of compound (5) (493 mg, 1.67 mmol) and triethylamine (708 ⁇ l, 5.00 mmol) in dimethylformamide (2 mL) was added, and the mixture was stirred at room temperature for 16 hours. The reaction solution was poured into ice-2 mol / L hydrochloric acid and extracted with ethyl acetate.
- the lyophilized formulation (1 vial) is made as follows:
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Pulmonology (AREA)
- Virology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Neurosurgery (AREA)
Description
Claims
Priority Applications (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/565,948 US7825146B2 (en) | 2003-07-30 | 2004-07-28 | Sulfonamide derivative having isoxazole ring |
JP2005512497A JPWO2005012268A1 (ja) | 2003-07-30 | 2004-07-28 | イソオキサゾール環を有するスルホンアミド誘導体 |
EP04748009A EP1650199A4 (en) | 2003-07-30 | 2004-07-28 | SULPHONAMIDE DERIVATIVE WITH ISOXAZOL RING |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003282354 | 2003-07-30 | ||
JP2003-282354 | 2003-07-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005012268A1 true WO2005012268A1 (ja) | 2005-02-10 |
Family
ID=34113774
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2004/010697 WO2005012268A1 (ja) | 2003-07-30 | 2004-07-28 | イソオキサゾール環を有するスルホンアミド誘導体 |
Country Status (5)
Country | Link |
---|---|
US (1) | US7825146B2 (ja) |
EP (1) | EP1650199A4 (ja) |
JP (1) | JPWO2005012268A1 (ja) |
TW (1) | TW200510350A (ja) |
WO (1) | WO2005012268A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2007085451A3 (en) * | 2006-01-27 | 2007-12-21 | Novartis Ag | 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents |
JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9889132B2 (en) * | 2014-07-04 | 2018-02-13 | Special Product's Line S.p.A. | Pharmaceutical compositions for the treatment of psoriasis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063194A1 (fr) * | 1999-04-19 | 2000-10-26 | Shionogi & Co., Ltd. | Derives de sulfonamide possedant des noyaux oxadiazole |
WO2001083431A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Inhibiteurs de mmp-12 |
WO2001083461A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Derives de thiazole et d'oxazole |
WO2002028844A1 (fr) * | 2000-09-29 | 2002-04-11 | Shionogi & Co., Ltd. | Dérivés thiazole ou oxazole |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE69737605T2 (de) | 1996-01-23 | 2008-04-03 | Shionogi & Co., Ltd. | Sulfonierte aminosäurederivate und metalloproteinase-inhibitoren, die diese enthalten |
ES2311571T3 (es) * | 1996-04-12 | 2009-02-16 | G.D. Searle Llc | Derivados de bencenosulfonamida sustituidos como profarmacos de inhibidores de cox-2. |
ID29293A (id) | 1997-07-22 | 1999-01-28 | Shionogi & Co | KOMPOSISI UNTUK MENGOBATI ATAU MENCEGAH GLOMERULOPATI (Pecahan dari No. W20000054) |
CA2406685C (en) | 2000-04-21 | 2006-10-31 | Shionogi & Co., Ltd. | Oxadiazole derivatives having anticancer effects |
AU2001248765A1 (en) | 2000-04-21 | 2001-11-12 | Shionogi And Co., Ltd. | Oxadiazole derivatives having therapeutic or preventive efficacies against glomerular disorders |
-
2004
- 2004-07-28 WO PCT/JP2004/010697 patent/WO2005012268A1/ja active Application Filing
- 2004-07-28 EP EP04748009A patent/EP1650199A4/en not_active Withdrawn
- 2004-07-28 JP JP2005512497A patent/JPWO2005012268A1/ja active Pending
- 2004-07-28 US US10/565,948 patent/US7825146B2/en not_active Expired - Fee Related
- 2004-07-29 TW TW093122644A patent/TW200510350A/zh unknown
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000063194A1 (fr) * | 1999-04-19 | 2000-10-26 | Shionogi & Co., Ltd. | Derives de sulfonamide possedant des noyaux oxadiazole |
WO2001083431A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Inhibiteurs de mmp-12 |
WO2001083461A1 (fr) * | 2000-04-28 | 2001-11-08 | Shionogi & Co., Ltd. | Derives de thiazole et d'oxazole |
WO2002028844A1 (fr) * | 2000-09-29 | 2002-04-11 | Shionogi & Co., Ltd. | Dérivés thiazole ou oxazole |
Non-Patent Citations (1)
Title |
---|
See also references of EP1650199A4 * |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008545767A (ja) * | 2005-06-08 | 2008-12-18 | ノバルティス アクチエンゲゼルシャフト | 多環式オキサジアゾールまたはイソキサゾールおよびsip受容体リガンドとしてのそれらの使用 |
WO2007085451A3 (en) * | 2006-01-27 | 2007-12-21 | Novartis Ag | 3,5-di (aryl or heteroaryl) isoxazoles and 1, 2, 4-oxadiazoles as s1p1 receptor agonists, immunosuppresssive and anti -inflammatory agents |
JP2009524611A (ja) * | 2006-01-27 | 2009-07-02 | ノバルティス アクチエンゲゼルシャフト | 逆イソキサゾール |
Also Published As
Publication number | Publication date |
---|---|
TW200510350A (en) | 2005-03-16 |
EP1650199A1 (en) | 2006-04-26 |
JPWO2005012268A1 (ja) | 2006-09-14 |
US20060183770A1 (en) | 2006-08-17 |
US7825146B2 (en) | 2010-11-02 |
EP1650199A4 (en) | 2008-11-19 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6897237B2 (en) | MMP-12 inhibitors | |
JP3621427B2 (ja) | 糸球体障害治療または予防剤 | |
JP4219810B2 (ja) | Mmp阻害作用を有するスルホンアミド誘導体 | |
WO2007102392A1 (ja) | Mmp-13選択的阻害剤 | |
JP2004530709A (ja) | 抗腫瘍剤としての使用のためのベンゾイルスルホンアミドおよびスルホニルベンズアミジン | |
KR100542780B1 (ko) | 항암 효과를 갖는 옥사디아졸 유도체 | |
WO2003080042A1 (fr) | Inhibiteur de decomposition pour matrice extracellulaire de cartilage | |
KR20010113820A (ko) | 옥사디아졸 고리를 갖는 술폰아미드 유도체 | |
WO2000015213A1 (fr) | Agent de prevention ou de traitement de l'insuffisance cardiaque congestive | |
US6949566B2 (en) | Thiazole and oxazole derivatives | |
JP2002538146A (ja) | ジヘテロ−置換メタロプロテアーゼ阻害剤 | |
WO2001083461A1 (fr) | Derives de thiazole et d'oxazole | |
WO2001083464A1 (fr) | Derives d'oxadiazole efficaces en matiere de traitement ou de prevention d'etats pathologiques glomerulaire | |
WO2000058304A1 (fr) | Derives sulfonamides heterocycliques | |
WO2005012268A1 (ja) | イソオキサゾール環を有するスルホンアミド誘導体 | |
WO2000058278A1 (en) | β-AMINO ACID DERIVATIVES | |
JPWO2006028038A1 (ja) | Mmp−13を選択的に阻害するスルホンアミド誘導体 | |
WO2000058280A1 (fr) | Derives de sulfonamide carbocyclique | |
WO1998033777A1 (fr) | Composes ayant une activite inhibant la metalloprotease | |
WO2003080041A1 (fr) | Remede contre l'arthrite deformante | |
JPH05194424A (ja) | 新規なピリミジン誘導体及び該誘導体を有効成分とする医薬 | |
MXPA00000712A (en) | Therapeutic or prophylactic agent for glomerulopathy |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2005512497 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006183770 Country of ref document: US Ref document number: 10565948 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004748009 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2004748009 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 10565948 Country of ref document: US |